India on Monday got its third COVID-19 vaccine after Covishield and Covaxin, as the Centre has approved emergency use of Sputnik V vaccine.
Sputnik V is a COVID-19 vaccine developed by Russia.
Ready for a challenge? Click here to take our quiz and show off your knowledge!
Notably, Dr Reddy’s Laboratories, the Hyderabad-based pharmaceutical company, last week sought Centre’s approval for Sputnik V vaccine to be used in India.
The Russian Direct Investment Fund (RDIF) partnered with Dr Reddy’s in September 2020 to conduct clinical trials of Sputnik V in India.
Along with Dr Reddy’s the RDIF partnered with Virchow Biotech Private Limited in March to produce up to 200 million doses per year of Sputnik V in India.
Ready for a challenge? Click here to take our quiz and show off your knowledge!
It has also partnered with Stelis Biopharma Pvt Ltd and Panacea Biotec earlier in April as well to produce 200 million and 100 million doses per year of Sputnik V in the country.
Also read: Congress likely to use ‘Assam model’ for Uttar Pradesh Assembly elections next year
India got Sputnik V as the third COVID-19 vaccine as many States in the Country have flagged shortage of Covid-19 vaccine doses.
Sputnik-V claims that it is affordable vaccine and can be “stored at a temperature of +2 to +8°C “.
India is currently using Serum Institute of India (SII)-manufactured Covishield and Bharat Biotech’s Covaxin.
With the second wave of COVID-19 hitting India hard, the approval of Sputnik V as the third vaccine in the Country has come as a major relief.
The vaccine approval will help in boosting supplies that were petering out.
Also read: Covid19 claims 904 more people in India in last 24 hours; 1.68 lakh new positive cases detected
India is currently facing the second wave of COVID-19 pandemic with the number of new cases increasing each day.
On Monday, the country hit a new coronavirus infection record with 1,68,912 new cases, the highest single-day rise so far.